You just read:

Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA's Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosis

News provided by

Spherix Global Insights

Nov 21, 2017, 11:31 EST